BiOptix Announces support for the 9th Annual Next Generation Protein Therapeutics Summit
BOULDER, Colo. and SAN FRANCISCO, June 5, 2014 /PRNewswire/ — BiOptix is pleased to announce its participation in the 9(th) annual Next Generation Protein Therapeutics Summit, being held in conjunction with the 2(nd) annual Bioconjugates: From Targets to Therapeutics and the Protein Aggregation, Stability & Solubility Summits from June 4 – 6(th) in San Francisco. At the event, BiOptix is presenting new protein binding data that has been generated for customers on the BiOptix 404pi during the first half of 2014.
“Proteomics is a direct compliment for the BiOptix SPR platform,” noted Ken Wilczek, Vice President, Sales & Marketing for BiOptix. “The BiOptix 404pi has the ability to measure protein-protein kinetics as well as protein-small molecule binding interactions–both of which are critical in the research, selection and validation of protein compounds as well as in the drug discovery process.” BiOptix will present new protein-protein and protein-small molecule data throughout the next several days at the combined summit. BiOptix is also using the event to highlight the BiOptix Innovators Program–its industry-leading instrumentation demo program. Details about the BiOptix Innovators Program, as well as how to participate, can be found at: http://www.bioptix.com/products/innovators-program
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip’s gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction–with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com